28 Jan. 2021. L’objet de ce document est de fournir des orientations provisoires sur la sécurité biologique en laboratoire applicable à l’analyse d’échantillons cliniques issus de patients.
Slideset updated regularly to include the latest data and guidance on COVID-19 risk and management in special populations, including children and pregnant women, and persons with comorbidities.
26 March 2021 Slideset updated regularly to include the latest data on the evolution and duration of COVID-19 symptoms and prevalence and duration of natural immunity.
Orientations provisoires, 2 février 2021
e document est une mise à jour des orientations provisoires de l’Organisation mondiale de la Santé (OMS) intitulées Coronavirus disease (COVID-19) outbreak: rights, roles and responsibilities of health workers, including key considerations... for occupational safety and health,publiées le 18 mars 2020(1). La présente version, qui se fonde sur les données récentes disponibles, fournit des conseils sur les mesures de santé et de sécurité au travail pour les agents de santé et les services de santé au travail dans le contexte de la pandémie de COVID-19. De plus, elle actualise les droits et responsabilités en matière de santé et de sécurité au travail des agents de santé conformément aux normes de l’Organisation internationale du Travail (OIT).
more
A WHO-UNICEF joint statement encouraging greater health commodity supply chain integration for temperature-sensitive pharmaceuticals where appropriate, 19 November 2020
“Guide to facilitate the implementation of the WHO/UNICEF “Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines” for Africa
Biweekly situation reports
This document aims to describe a minimum set of surveillance activities recommended at the national level to detect and monitor the relative prevalence of SARS-CoV-2 variants and outline a set of activities for the characterization and assessment of risk posed by these variants. A set of indicators ...is also provided to standardize monitoring and public reporting of variant circulation.
The document is primarily intended for national and sub-national public health authorities and partners who support implementation of surveillance for SARS-CoV-2 variants
more
Vaksen MMRV (Lawoujòl, Malmouton,
Ribeyòl, ak Varisèl): Sa Ou Dwe Konnen
Vaksen kont Varisèl (Saranpyon):Sa Ou Dwe Konnen
10 BAGAY OU K A FÈ POU JERE SENTÒM
COVID-19 OU YO L AK AY OU
KOWONAVIRIS AK ASIRANS SANTE OU: KONPRANN PRENSIP DEBAZ YO
Konsèy pou Gwo Fanmi oswa Moun ki Fanmi k ap Viv nan yon Menm Kay
Pwoteje Manje ak Dlo Apre yon Dezas oswa Sitiyasyon Ijans
Evite Maladi Apre Yon Dezas
Kisa kansè ye?
Yon gid pou pasyan yo ak fanmi yo
Rete lwen danje apre yon Siklòn
Vaksen Kont Epatit AKi Sa Ou Bezwen Konnen